BiotechTube
Home/Immutep/Deanne Miller
DM

Deanne Miller

Chief Operating Officer, General Counsel & Company Secretary

Immutep

Therapeutic Areas

OncologyAutoimmune Diseases

Immutep Pipeline

DrugIndicationPhase
Eftilagimod alfa (efti)1st Line Non-Small Cell Lung Cancer (NSCLC)Phase III
IMP761Autoimmune Diseases (e.g., Lupus, RA)Preclinical
IMP731Ulcerative Colitis, PsoriasisPhase II
LAG525 (ieramilimab)Various Solid TumorsPhase II
Novel Small Molecule LAG-3 AntagonistOncologyResearch

Leadership Team at Immutep

MV
Marc Voigt
Chief Executive Officer & Executive Director
FT
Frédéric Triebel
Chief Scientific Officer & Executive Director
CM
Christian Mueller
Chief Development Officer
View full Immutep profile